 Following my post-doctoral studies at the University of Toronto, I was trying to make a decision on what the next step was for my career, and at the time Chris Goodenow had just set up his large-scale e-new vidogenesis of the mammalian genome to discover new mutations in the genome that affected the immune system. And I think it was this discovery tool that really, again, piqued my interest working in immunology. What I like to do has been involved in new discoveries, and Chris's group is definitely a large group that work almost exclusively on doing that. I've been establishing a group for the last several years, and one of the key areas that we've set up is a joint centre with the Chinese, which we call the China-Australia Centre for Phenomics Research, and that comes under Chris's broad immunogenomics lab. Our research is really to discover operations or mutations in the genome code that affect the immune system with a special emphasis on trying to understand different viral infections, including influenza virus, and also trying to get a handle on some of these chronic infections, such as hepatitis B virus, which is a big issue in China. So this centre was opened in 2008 by the Vice-Chancellor of the ANU and the President of the Chinese Academy of Sciences. It was one of two large joint centres that were funded by the Chinese government and the Australian government at the time. It involves myself as the Australian director here at the John Curtin School of Medical Research with Professor Hong Tang, who is the director of the Centre for Infection and Immunity at the Institute of Biophysics in the Chinese Academy of Sciences in Beijing. So we meet twice a year to discuss projects and exchange ideas around new discoveries in the immune system. One of the other benefits of being involved in the China-Australia Centre for Phenomics Research is that we have access to BGI, which is a large-scale, next-generation genome sequencing facility in Shenzhen, in China, and so we've set up a collaboration with them to do some large-scale sequencing, and this has proven to be a very positive collaboration for us in terms of fast turnaround times for the mutation detection work that we do. China is really investing very heavily in their research at the moment, so they're putting in a lot of money, building a lot of new buildings and infrastructure, and recruiting a lot of top scientists back to their country to lead the charge. So they're on a very big growth curve for research and research investment, and the thing about China is they have a lot of people and a lot of people power, and so they'll benefit from that, and we'll benefit from that, no collaboration, and we've had a number of their staff come and spend time here at the John Curtin School, and in the future we're looking to set up a bi-national laboratory with them to make it a true joint centre in that respect.